Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Astellas’s gene therapy aspirations crumble
AT132 has prompted more safety concerns, this time at a lower dose than before.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
